#United States #San Diego #diagnostics #QuidelOrtho #Q1 2026

QuidelOrtho Reports First Quarter 2026 Financial Results

QuidelOrtho Corporation (Nasdaq: QDEL) has announced its financial performance for the first quarter ending March 29, 2026. The results highlight both challenges and opportunities in the company’s ongoing commitment to innovative in vitro diagnostics. With total revenues reaching $620 million, QuidelOrtho experienced fluctuations across several business segments, a pattern reflecting both market conditions and company strategy.

Key Highlights

1. Total Revenue: Overall revenue showed a marked year-on-year decline; down 10.5% compared to the previous year’s period. Despite these challenges, the company remains optimistic about long-term growth.

2. Point-of-Care Revenue: Here, revenue plummeted by approximately 34% year-on-year, totaling $113 million. The decrease is attributed primarily to a notably weaker respiratory season in comparison to the same period in 2025. This decline poses questions about future forecasting, considering respiratory diagnostics have traditionally been a strong revenue stream for the company.

3. Labs Revenue: Revenue from laboratory diagnostics reached $353 million, reflecting a decline of 5%. Notably, the slowdown in sales from distributors in China has significantly impacted results, attributed in part to existing changes expected from the China National Health Security Administration (NHSA) affecting pricing guidelines for in vitro diagnostics (IVD).

4. Immunohematology Growth: On a more positive note, immunohematology revenues grew by 8%, driven largely by market demand in North America, China, and JPAC regions. This segment shows the company’s ability to adapt and thrive despite a challenging environment in other areas.

5. Financial Loss Metrics: QuidelOrtho reported a GAAP net loss of $92 million and a GAAP diluted loss per share at $1.35. However, adjusted EBITDA reached $109 million, showcasing areas where operational efficiencies can be focused on improving margins moving forward.

Future Prospects and Guidance

Following the announcement of its Q1 results, President and CEO Brian J. Blaser conveyed the company’s assessment of its market position. Blaser emphasized, “Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption.” Importantly, he reassured stakeholders that the underlying business remains solid and that they are committed to improving adjusted EBITDA margins moving forward.

In April, QuidelOrtho completed the acquisition of LEX Diagnostics, an ultra-fast molecular diagnostics platform aimed at enhancing point-of-care testing capabilities. This strategic move places the company in a prime position for innovation in diagnostic solutions and is expected to drive sustainable growth initiatives.

QuidelOrtho’s full-year financial guidance has also been revised. The updated guidance now projects total revenues between $2.70 - $2.75 billion, alongside expected adjusted EBITDA of $615 - $630 million, demonstrating the company’s resilient strategies in dealing with market turbulence.

Conclusion: While QuidelOrtho faces certain headwinds from market dynamics like geopolitical issues and regulatory adjustments, their commitment to advancing innovative diagnostics and adapting to challenges positions them favorably for the future. Engaging in strategic acquisitions and focusing on key growth areas, the company aims to redefine its path in the evolving diagnostics landscape. Investors and market observers will be keen to watch how these strategies unfold through 2026.

For further detailed information, please refer to the complete financial results presentation available on QuidelOrtho’s Investor Relations page.